VitaNova Life Sciences (VNOV) Cost of Revenue (2017 - 2025)
VitaNova Life Sciences (VNOV) reported Cost of Revenue of $2900.0 for Q4 2025, up 1723.9% on a YoY basis from $159.0 in Q4 2024, and down 91.74% quarter-over-quarter from $35118.0 in Q3 2025.
VitaNova Life Sciences (VNOV) Cost of Revenue (2017 - 2025) Analysis & Trends
VitaNova Life Sciences has reported Cost of Revenue for 3 years, with the latest figure at $2900.0 in Q4 2025.
- For the quarter ending Q4 2025, Cost of Revenue rose 1723.9% year-over-year to $2900.0; the trailing twelve-month figure through Jan 2026 stood at -$244910.0 (down 911.71% YoY), and the FY2025 full-year result was $7666.0, down 66.2% from the prior year.
- Cost of Revenue for Q4 2025 stood at $2900.0, down from $35118.0 in the prior quarter.
- The five-year high for Cost of Revenue was $35118.0 in Q3 2025, with the low at -$282928.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 92.25 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 74.77 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 58.44 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 2.30 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | 315.39 Mn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 9.67 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | 379.70 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 19,352.00 |
| 10 | VitaNova Life Sciences | - | - | 316,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | 2,900.00 |
| Oct 31, 2025 | 2,900.00 |
| Jul 31, 2025 | 35,118.00 |
| Jul 31, 2025 | 35,118.00 |
| Apr 30, 2025 | -282,928.00 |
| Apr 30, 2025 | -282,928.00 |
| Jan 31, 2025 | 300.00 |
| Jan 31, 2025 | 300.00 |
| Oct 31, 2024 | 159.00 |
| Oct 31, 2024 | 159.00 |
| Jul 31, 2024 | 7,030.00 |
| Jul 31, 2024 | 7,030.00 |
| Apr 30, 2024 | 22,683.00 |
| Apr 30, 2024 | 22,683.00 |
| Oct 31, 2017 | 28,400.00 |
| Oct 31, 2017 | 28,400.00 |
| Jul 31, 2017 | 2,900.00 |
| Jul 31, 2017 | 2,900.00 |